News
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer rapid oral abstract session and a presentation by Dr. Rikke Eefsen discussing the CA209-8TY trial, a randomized phase 2 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback